Clinical trial
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the…
NCT00060489 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00060489 |
|---|---|
| Title | Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder, Depression, Bipolar |
| Intervention type | Drug |
| Interventions | SEROQUEL (quetiapine fumarate) Tablets |
| Start date | Sep 1, 2002 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | May 8, 2003 |
| Last update posted | Jan 26, 2011 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: